Apitegromab: Revision history

12 November 2023

• curprev 10:4710:47, 12 November 2023 Citation bot talk contribs 4,771 bytes −14 Add: s2cid, pmc, pmid. Removed proxy/dead URL that duplicated identifier. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar undo

11 November 2023

• curprev 03:3003:30, 11 November 2023 Davemck talk contribs m 4,785 bytes −37 rmv duplicate parm undo
• curprev 02:2302:23, 11 November 2023 Reba16 talk contribs 4,822 bytes +2,107 No edit summary undo

10 November 2023

• curprev 18:3918:39, 10 November 2023 Ira Leviton talk contribs m 2,715 bytes +1 Fixed a reference. Please see Category:CS1 errors: invisible characters. undo

9 November 2023

• curprev 17:3817:38, 9 November 2023 Buidhe talk contribs 2,714 bytes +34 added Category:Myostatin inhibitors using HotCat undo
• curprev 17:3817:38, 9 November 2023 Buidhe talk contribs 2,680 bytes +37 added Category:Spinal muscular atrophy using HotCat undo
• curprev 17:3817:38, 9 November 2023 Buidhe talk contribs 2,643 bytes +36 added Category:Monoclonal antibodies using HotCat undo
• curprev 17:3517:35, 9 November 2023 Buidhe talk contribs 2,607 bytes +2,607 ←Created page with ''''Apitegromab''' (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy. It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin. It does not bind to active myostatin, activin A, active BMP9/10 or TGFβ1 that all operate on the activin type 2 receptors.<ref>{{cite journal |last1=Barrett |fir...'